Entry
Name
Coronavirus disease - COVID-19 - Mesocricetus auratus (golden hamster)
Description
Coronavirus disease of 2019 (COVID-19) is a highly contagious respiratory infection that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infects alveolar epithelial cells [mainly alveolar epithelial type 2 (AEC2) cells] through the angiotensin-converting enzyme 2 (ACE2) receptor. Upon the occupancy of ACE2 by SARS-CoV-2, the increased serum level of free Angiotensin II (Ang II) due to a reduction of ACE2-mediated degradation promotes activation of the NF-kappa B pathway via Ang II type 1 receptor (AT1R), followed by interleukin-6 (IL-6) production. SARS-CoV-2 also activates the innate immune system; macrophage stimulation triggers the overproduction of pro-inflammatory cytokines, including IL-6, and the "cytokine storm", which results in systemic inflammatory response syndrome and multiple organ failure. The combined effects of complement activation, dysregulated neutrophilia, endothelial injury, and hypercoagulability appear to be intertwined to drive the severe features of COVID-19.
Class
Human Diseases; Infectious disease: viral
BRITE hierarchy
Pathway map
Ortholog table
Organism
Mesocricetus auratus (golden hamster) [GN:
maua ]
Gene
101839499 Nfkb1; nuclear factor NF-kappa-B p105 subunit isoform X1 [KO:K02580 ]
101840696 Tnfrsf1a; tumor necrosis factor receptor superfamily member 1A [KO:K03158 ]
101834358 Stat3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692 ]
101841789 Csf2; granulocyte-macrophage colony-stimulating factor [KO:K05427 ]
101825097 Fau; ubiquitin-like protein fubi and ribosomal protein S30 [KO:K02983 ]
101829440 Rpl17; LOW QUALITY PROTEIN: 60S ribosomal protein L17 [KO:K02880 ]
101831114 LOW QUALITY PROTEIN: low affinity immunoglobulin gamma Fc region receptor III [KO:K06472 ]
101823280 Pik3cb; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922 ] [EC:2.7.1.153 ]
101828739 Pik3cd; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X4 [KO:K00922 ] [EC:2.7.1.153 ]
101843471 Pik3ca; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922 ] [EC:2.7.1.153 ]
101829045 Pik3r2; phosphatidylinositol 3-kinase regulatory subunit beta isoform X2 [KO:K02649 ]
101835039 Pik3r1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X1 [KO:K02649 ]
101831400 phosphatidylinositol 3-kinase regulatory subunit gamma isoform X1 [KO:K02649 ]
101824564 Plcg1; LOW QUALITY PROTEIN: 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 [KO:K01116 ] [EC:3.1.4.11 ]
101828578 Myd88; myeloid differentiation primary response protein MyD88 [KO:K04729 ]
101844616 Tab2; TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 isoform X1 [KO:K04404 ]
101824408 Nlrp3; NACHT, LRR and PYD domains-containing protein 3 isoform X1 [KO:K12800 ]
101826955 Mavs; mitochondrial antiviral-signaling protein isoform X1 [KO:K12648 ]
101827798 Stat1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220 ]
101830537 Stat2; signal transducer and activator of transcription 2 [KO:K11221 ]
101836026 Eif2ak2; interferon-induced, double-stranded RNA-activated protein kinase isoform 1 [KO:K16195 ] [EC:2.7.11.1 ]
101834425 C5ar1; C5a anaphylatoxin chemotactic receptor 1 isoform X1 [KO:K04010 ]
101825252 C1qb; complement C1q subcomponent subunit B isoform X1 [KO:K03987 ]
101823015 Masp1; mannan-binding lectin serine protease 1 isoform X1 [KO:K03992 ] [EC:3.4.21.-]
Compound
Reference
Authors
Harrison AG, Lin T, Wang P
Title
Mechanisms of SARS-CoV-2 Transmission and Pathogenesis.
Journal
Reference
Authors
Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G
Title
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19.
Journal
Reference
Authors
Battagello DS, Dragunas G, Klein MO, Ayub ALP, Velloso FJ, Correa RG
Title
Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission.
Journal
Reference
Authors
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM
Title
COVID-19: Immunology and treatment options.
Journal
Reference
Authors
Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T
Title
How COVID-19 induces cytokine storm with high mortality.
Journal
Reference
Authors
Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I
Title
COVID-19 cytokine storm: The anger of inflammation.
Journal
Reference
Authors
Farooqi F, Dhawan N, Morgan R, Dinh J, Nedd K, Yatzkan G
Title
Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
Journal
Reference
Authors
Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, Francois B, Seve P
Title
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.
Journal
Reference
Authors
Kiselevskiy M, Shubina I, Chikileva I, Sitdikova S, Samoylenko I, Anisimova N, Kirgizov K, Suleimanova A, Gorbunova T, Varfolomeeva S
Title
Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?
Journal
Reference
Authors
Curran CS, Rivera DR, Kopp JB
Title
COVID-19 Usurps Host Regulatory Networks.
Journal
Reference
Authors
Quan C, Li C, Ma H, Li Y, Zhang H
Title
Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis.
Journal
Reference
Authors
Ahmed-Hassan H, Sisson B, Shukla RK, Wijewantha Y, Funderburg NT, Li Z, Hayes D Jr, Demberg T, Liyanage NPM
Title
Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Journal
Reference
Authors
Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP
Title
The trinity of COVID-19: immunity, inflammation and intervention.
Journal
Reference
Authors
Xia H, Cao Z, Xie X, Zhang X, Chen JY, Wang H, Menachery VD, Rajsbaum R, Shi PY
Title
Evasion of Type I Interferon by SARS-CoV-2.
Journal
Reference
Authors
Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA
Title
The molecular virology of coronaviruses.
Journal
Reference
Authors
Amor S, Fernandez Blanco L, Baker D
Title
Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage.
Journal
Reference
Authors
Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C
Title
Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Journal
Reference
Authors
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, Nemati M
Title
Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Journal
Reference
Authors
Merad M, Martin JC
Title
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.
Journal
Reference
Authors
South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA
Title
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
Journal
Reference
Authors
Furuhashi M, Moniwa N, Takizawa H, Ura N, Shimamoto K
Title
Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
Journal
Reference
Authors
Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V
Title
COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?
Journal
Reference
Authors
Kielian M
Title
Enhancing host cell infection by SARS-CoV-2.
Journal
Reference
Authors
Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD
Title
Complement as a target in COVID-19?
Journal
Reference
Authors
Noris M, Benigni A, Remuzzi G
Title
The case of complement activation in COVID-19 multiorgan impact.
Journal
Reference
Authors
Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S
Title
Rationale for targeting complement in COVID-19.
Journal
Reference
Authors
Teuwen LA, Geldhof V, Pasut A, Carmeliet P
Title
COVID-19: the vasculature unleashed.
Journal
Reference
Authors
Jodele S, Kohl J
Title
Tackling COVID-19 infection through complement-targeted immunotherapy.
Journal
Reference
Authors
Chauhan AJ, Wiffen LJ, Brown TP
Title
COVID-19: A collision of complement, coagulation and inflammatory pathways.
Journal
Reference
Authors
Colling ME, Kanthi Y
Title
COVID-19-associated coagulopathy: An exploration of mechanisms.
Journal
Reference
Authors
McFadyen JD, Stevens H, Peter K
Title
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
Journal
Reference
Authors
Shi M, Wang L, Fontana P, Vora S, Zhang Y, Fu TM, Lieberman J, Wu H
Title
SARS-CoV-2 Nsp1 suppresses host but not viral translation through a bipartite mechanism.
Journal
Reference
Authors
Paniri A, Akhavan-Niaki H
Title
Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
Journal
Reference
Authors
Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G
Title
Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Journal
Reference
Authors
Zhang S, Li L, Shen A, Chen Y, Qi Z
Title
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.
Journal
Related pathway
maua04610 Complement and coagulation cascades
maua04613 Neutrophil extracellular trap formation
maua04620 Toll-like receptor signaling pathway
maua04621 NOD-like receptor signaling pathway
maua04622 RIG-I-like receptor signaling pathway
maua04650 Natural killer cell mediated cytotoxicity
maua04670 Leukocyte transendothelial migration
KO pathway
LinkDB
All DBs